Atomoxetine Hydrochloride Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, 100 mg
Reference Brands: Strattera (USA)
Category:
Neurology
Atomoxetine Hydrochloride is available in Capsules
and strengths such as 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, 100 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Atomoxetine Hydrochloride is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Atomoxetine Hydrochloride can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Atomoxetine hydrochloride is a selective norepinephrine reuptake inhibitor (sNRI) used primarily for the treatment of attention deficit hyperactivity disorder (ADHD) in children, adolescents, and adults aged six years and older. It may be prescribed alone or in combination with stimulant medications, depending on individual patient needs. Atomoxetine works by increasing norepinephrine levels in the brain, enhancing executive functions such as self-motivation, sustained attention, inhibition control, working memory, reaction time, and emotional regulation.
Administered orally, atomoxetine provides a non-stimulant treatment option for ADHD with a lower potential for abuse compared to traditional stimulant therapies. Its effectiveness is comparable to commonly prescribed stimulant medications, such as methylphenidate, making it a valuable alternative for patients who cannot tolerate stimulants or require additional management strategies. Atomoxetine supports improved attention, focus, and behavioral control, contributing to better academic, social, and occupational functioning in individuals with ADHD. Its predictable pharmacokinetics and safety profile allow for consistent therapeutic outcomes under medical supervision.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing